|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Block TM, Mehta AS, Fimmel CJ and Jordan
R: Molecular viral oncology of hepatocellular carcinoma. Oncogene.
22:5093–5107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, et
al: Kurume Liver Cancer Study Group of Japan: Sorafenib for the
treatment of advanced hepatocellular carcinoma with extrahepatic
metastasis: A prospective multicenter cohort study. Cancer Med.
4:1836–1843. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harimoto N, Shirabe K, Ikegami T,
Yoshizumi T, Maeda T, Kajiyama K, Yamanaka T and Maehara Y:
Postoperative complications are predictive of poor prognosis in
hepatocellular carcinoma. J Surg Res. 199:470–477. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nollet F, Kools P and van Roy F:
Phylogenetic analysis of the cadherin superfamily allows
identification of six major subfamilies besides several solitary
members. J Mol Biol. 299:551–572. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halbleib JM and Nelson WJ: Cadherins in
development: Cell adhesion, sorting, and tissue morphogenesis.
Genes Dev. 20:3199–3214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Redies C, Vanhalst K and Roy F:
delta-Protocadherins: Unique structures and functions. Cell Mol
Life Sci. 62:2840–2852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morishita H and Yagi T: Protocadherin
family: Diversity, structure, and function. Curr Opin Cell Biol.
19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu JS, Koujak S, Nagase S, Li CM, Su T,
Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8,
the human homolog of PAPC, is a candidate tumor suppressor of
breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu X, Sui X, Li L, Huang X, Rong R, Su X,
Shi Q, Mo L, Shu X, Kuang Y, et al: Protocadherin 17 acts as a
tumour suppressor inducing tumour cell apoptosis and autophagy, and
is frequently methylated in gastric and colorectal cancers. J
Pathol. 229:62–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin X, Xiang T, Mu J, Mao H, Li L, Huang
X, Li C, Feng Y, Luo X, Wei Y, et al: Protocadherin 17 functions as
a tumor suppressor suppressing Wnt/β-catenin signaling and cell
metastasis and is frequently methylated in breast cancer.
Oncotarget. 7:51720–51732. 2016.PubMed/NCBI
|
|
13
|
Imoto I, Izumi H, Yokoi S, Hosoda H,
Shibata T, Hosoda F, Ohki M, Hirohashi S and Inazawa J: Frequent
silencing of the candidate tumor suppressor PCDH20 by epigenetic
mechanism in non-small-cell lung cancers. Cancer Res. 66:4617–4626.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen T, Long B, Ren G, Xiang T, Li L, Wang
Z, He Y, Zeng Q, Hong S and Hu G: Protocadherin20 acts as a tumor
suppressor gene: Epigenetic inactivation in nasopharyngeal
carcinoma. J Cell Biochem. 116:1766–1775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin
Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, et al:
Identifying autism loci and genes by tracing recent shared
ancestry. Science. 321:218–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Chim JC, Yang M, Ye J, Wong BC and
Qiao L: Role of PCDH10 and its hypermethylation in human gastric
cancer. Biochim Biophys Acta. 1823:298–305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhong X, Zhu Y, Mao J, Zhang J and Zheng
S: Frequent epigenetic silencing of PCDH10 by methylation in human
colorectal cancer. J Cancer Res Clin Oncol. 139:485–490. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang X, Yin X, Xiang T, Li H, Li F, Chen L
and Ren G: Protocadherin 10 is frequently downregulated by promoter
methylation and functions as a tumor suppressor gene in non-small
cell lung cancer. Cancer Biomark. 12:11–19. 2012.2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiu C, Bu X and Jiang Z: Protocadherin-10
acts as a tumor suppressor gene, and is frequently downregulated by
promoter methylation in pancreatic cancer cells. Oncol Rep.
36:383–389. 2016.PubMed/NCBI
|
|
20
|
Fang S, Huang SF, Cao J, Wen YA, Zhang LP
and Ren GS: Silencing of PCDH10 in hepatocellular carcinoma via de
novo DNA methylation independent of HBV infection or HBX
expression. Clin Exp Med. 13:127–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng QK, Lei YG, Lin YL, Ma JG and Li WP:
Prognostic value of protocadherin10 (PCDH10) methylation in serum
of prostate cancer patients. Med Sci Monit. 22:516–521. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN,
Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of
protocadherin 10, a novel tumor suppressor, is associated with poor
prognosis in patients with gastric cancer. Gastroenterology.
136:640–651.e1. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li M, Yan DG and Liu JL: Methylation
status of PCDH10 and RASSF1A gene promoters in colorectal cancer.
Zhonghua Yi Xue Za Zhi. 96:456–459. 2016.(In Chinese). PubMed/NCBI
|
|
24
|
Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC,
Tzeng ST, Chang CY, Lai YC, Yen SJ, Yu SL, et al: Protocadherin 10
suppresses tumorigenesis and metastasis in colorectal cancer and
its genetic loss predicts adverse prognosis. Int J Cancer.
135:2593–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakao S, Platek A, Hirano S and Takeichi
M: Contact-dependent promotion of cell migration by the
OL-protocadherin-Nap1 interaction. J Cell Biol. 182:395–410. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grove EA: Turning neurons into a nervous
system. Development. 135:2203–2206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Z, Yang Z, Peng X, Li Y, Liu Q and Chen
J: Nuclear factor-κB is involved in the protocadherin-10-mediated
pro-apoptotic effect in multiple myeloma. Mol Med Rep. 10:832–838.
2014.PubMed/NCBI
|
|
28
|
Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q
and Chen J: PCDH10 inhibits cell proliferation of multiple myeloma
via the negative regulation of the Wnt/β-catenin/BCL-9 signaling
pathway. Oncol Rep. 34:747–754. 2015.PubMed/NCBI
|
|
29
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bozulic L and Hemmings BA: PIKKing on PKB:
Regulation of PKB activity by phosphorylation. Curr Opin Cell Biol.
21:256–261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
